Skip to search formSkip to main contentSkip to account menu

Trastuzumab VC-seco-DUBA

Known as: ADC SYD985, Antibody-drug Conjugate SYD985, SYD985 
An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic… 
Review
2019
Review
2019
Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers… 
2018
2018
1014Background: SYD985, (vic-)trastuzumab duocarmazine, is a HER2-targeting antibody-drug conjugate with a cleavable linker… 
2017
2017
Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous… 
2016
2016
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu… 
Highly Cited
2015
Highly Cited
2015
Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug… 
Highly Cited
2015
Highly Cited
2015
SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin… 
Highly Cited
2014
Highly Cited
2014
A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation…